Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
NCT00211562 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2012-10-24
Summary
This research study helps to demonstrate that adding vitamins and fats (nutritional supplements) to a diet will help reduce body weight and improve the lipid profile. This will be done by examining the body weight and chemicals in the blood. The chemicals are the result of the brain using the fat that subjects eat in their diet. Some medications may also change the amount of these chemicals in a person's blood.
Conditions
Interventions
- DRUG
-
Olanzapine, Omega 3, Vitamin E+C
No adverse event nor SAE noted.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Medical Service Line ABRC
collaborator UNKNOWN -
US Department of Veterans Affairs
collaborator FED -
Augusta University
lead OTHER
Principal Investigators
-
Peter Buckley, M.D. · VA MC/Medical College of Georgia
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2006-01-31
Countries
- United States
Study Locations
More Related Trials
-
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
NCT01355952 ·Status: COMPLETED ·Phase: NA
-
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00100776 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
NCT00088478 ·Status: COMPLETED ·Phase: PHASE3
-
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
NCT00833976 ·Status: COMPLETED ·Phase: PHASE4
-
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
NCT00083668 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
NCT05542264 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281 ·Status: COMPLETED ·Phase: PHASE3
-
Cardio Risk of Acute Schizophrenia Olanzapine Duke
NCT00672464 ·Status: WITHDRAWN ·Phase: PHASE4
-
Acute Olanzapine and Lipid Response
NCT04181385 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00148564 ·Status: COMPLETED ·Phase: PHASE4
-
A First In Human Study Of PF-00184562 In Healthy Volunteers
NCT00150215 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
NCT00485823 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
NCT05402111 ·Status: COMPLETED ·Phase: PHASE1
-
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
NCT01043458 ·Status: COMPLETED ·Phase: PHASE1
-
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571 ·Status: COMPLETED ·Phase: PHASE4
-
Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
NCT00078039 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
NCT00793780 ·Status: COMPLETED ·Phase: NA
-
Study in Adolescents With Schizophrenia or Bipolar Disorder
NCT00982020 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
NCT00640510 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00088049 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012 ·Status: COMPLETED ·Phase: PHASE4
-
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
NCT00089869 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Characterizing Response to Antipsychotics in Schizophrenia
NCT06159322 ·Status: RECRUITING
-
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
NCT00210769 ·Status: COMPLETED ·Phase: PHASE3